|
The information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Dear Readers, It's hard to believe that another year has passed so quickly and it is already time for our yearly summer vacation. There will not be an update to the information section of the web site for the months of July and August. See you in September. Have a great summer, with best regards, Shara Rosen. Abbott Laboratories and Promega Corporation have entered into an agreement to provide nucleic acid extraction products for infectious disease testing. The collaboration will provide a system to purify and extract viral RNA from patient samples using Abbott's magnetic particle technology. The RNA extraction system will be used in Abbott's m1000, an automated sample preparation system for molecular diagnostics that will be introduced in 2003. Abbott Laboratories has formed a worldwide marketing and distribution agreement with Artus GmbH for a commercial test to detect a form of the coronavirus suspected of causing Severe Acute Respiratory Syndrome (SARS). The test was introduced by Artus in April to countries in Asia and Europe and has been provided to laboratories under the direction of the World Health Organization and other major clinical sites conducting studies on the SARS virus. Under the agreement, Artus will manufacture the PCR test and Abbott will market and distribute it initially for use on the Roche LightCycler thermal cycler system in the U.S., Canada, Germany, the U.K. and Austria and on the Applied Biosystems ABI Prism 7000 Sequence Detection System for worldwide distribution. Abbott will assist Artus in submitting this test to the U.S. Food and Drug Administration as quickly as possible. Affymetrix, Inc. has launched its GeneChip brand CustomSeq SARS Pathogen Detection Resequencing Array, designed to enable scientists to rapidly resequence different isolates of the virus that causes SARS. Focus Technologies has developed a real-time PCR test designed to detect the presence of the coronavirus associated with the development of severe acute respiratory syndrome (SARS) in patients. The detection of the genomic RNA from the coronavirus associated with SARS is based upon reverse transcription of specific viral genomic RNA sequences followed by PCR amplification. This methodology was developed by the Bernhard-Nocht Institute (Hamburg, Germany) and described by the World Health Organization. Prometheus Laboratories Inc. has introduced its PRO-GenoLogix Lactose Intolerance assay, a genetic test to help physicians identify a specific genetic cause of lactose intolerance. Roche Diagnostics and Innogenetics have launched a first series of new microbiology tests for the rapid detection and differentiation of the human pathogens Pseudomonas aeruginosa, Staphylococcus aureus and coagulase-negative Staphylococci, Enterococcus faecalis and E. faecium, and Candida albicans. The tests are based on newly developed DNA-free reagent technologies designed for real-time PCR detection on Roche’s LightCycler instrumentation.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: June 2, 2003 |
![[Page Banner Image]](images/hmole.gif){kind=small}
